The tablet formulation of zanubrutinib (Brukinsa; BeOne) has become authorised for all 5 indications across many hematological cancers.Nala's MLD was recognized far too late for her to get treated. She is already not able to wander or speak, and needs to be tube-fed.“MLD can be a devastating sickness that profoundly affects the quality of life of